Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CreaVax-RCC
- Development stage
- Phase 3
- Lead developer
- JW CreaGene
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
CreaVax-RCC is an autologous dendritic cell-based cancer vaccine developed by JW CreaGene for the treatment of metastatic renal cell carcinoma (RCC). The therapy is produced by isolating mononuclear cells from a patient's blood and differentiating them into dendritic cells. These dendritic cells are then sensitized *ex vivo* with the patient's own tumor lysate and Keyhole Limpet Hemocyanin (KLH) as an immune adjuvant. Once injected back into the patient intradermally, the activated dendritic cells migrate to lymph nodes and induce a cancer-specific immune response, primarily through the activation of cytotoxic T lymphocytes (CTLs) that can target and kill tumor cells. CreaVax-RCC received conditional approval in South Korea in 2007 for metastatic RCC.
- Brand names
- CreaVax-RCC
- Other names
- JW-CreaVax-RCC
Beyond the preview
Go deeper on CreaVax-RCC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CreaVax-RCC.